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 1 
ABSTRACT 2 
Purpose: Evidence regarding functional impairment in people with severe mental disorders 3 
(SMD) is sparse in low and middle-income countries. The aim of this study was to identify factors 4 
associated with functional impairment in people with enduring SMD in a rural African setting.  5 
Methods: A cross-sectional study was conducted at the baseline of a health service intervention 6 
trial. A total of 324 participants were recruited from an existing community-ascertained cohort of 7 
people with SMD (n= 218), and attendees at the Butajira General Hospital psychiatric clinic (n= 8 
106). Inclusion criteria defined people with SMD who had ongoing need for care: those who were 9 
on psychotropic medication, currently symptomatic or had a relapse in the preceding two years. 10 
The World Health Organization Disability Assessment schedule (WHODAS-2.0) and the Butajira 11 
Functioning Scale (BFS), were used to assess functional impairment. Multivariable negative 12 
binomial regression models were fitted to investigate the association between demographic, socio-13 
economic and clinical characteristics, and functional impairment.  14 
Results: Increasing age, being unmarried, rural residence, poorer socio-economic status, symptom 15 
severity, continuous course of illness, medication side effects and internalized stigma were 16 
associated with functional impairment across self-reported and caregiver responses for both the 17 
WHODAS and the BFS. Diagnosis per se was not associated consistently with functional 18 
impairment.   19 
Conclusion: To optimize functioning in people with chronic SMD in this setting, services need to 20 
target residual symptoms, poverty, medication side effects and internalized stigma. Testing the 21 
impact of community interventions to promote recovery will be useful. Advocacy for more 22 
tolerable treatment options is warranted.  23 
Key words: Severe mental disorder, disability, low and middle income countries, schizophrenia, 24 
bipolar disorder, major depressive disorder  25 
 26 
 27 
 28 
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Background  1 
Severe mental disorders (SMD), including schizophrenia, bipolar disorder and major depressive 2 
disorder with psychotic features, can be highly disabling illnesses [1-3]. The functional impairment 3 
seen in these conditions includes the compromised ability to work, to engage in interpersonal 4 
relationships, to care for oneself, and to participate in community activities [4]. In large, 5 
representative cohorts of people with schizophrenia in Finland [5], impairment in social 6 
functioning was present in more than 80% of participants. In a  comparative study of manic or 7 
hypomanic, euthymic and depressed patients and healthy controls, 30 to 50% of people with 8 
bipolar disorder experienced significant social disability [6]. Data from the World Health Survey 9 
indicates that major depressive disorder results in the greatest disability compared with other 10 
chronic physical diseases [7].  11 
There are very few population-based studies on the functional outcome of SMD from low- and 12 
middle-income countries (LMICs). The level of functioning of a population-based study of people 13 
with schizophrenia, bipolar disorder and severe major depressive disorder in rural Ethiopia was 14 
significantly lower than the normative value for the general population [8-10]. In studies 15 
comparing the level of functional impairment in different diagnostic categories, a mixed picture 16 
emerges, with some finding greater impairment in people with schizophrenia [11,12] and other 17 
studies showing that symptom severity was more predictive of functional impairment than clinical 18 
diagnosis [13,14]. 19 
Several studies, mostly from high income countries, identified factors that are associated with 20 
functional impairment in people with SMD: socio-demographic characteristics (male sex, older 21 
age, single or divorced marital status, urban residence, and lower socio-economic status) [15-18], 22 
illness characteristics (severity of negative and positive symptoms, long duration of untreated 23 
psychoses, co-morbid substance abuse, medication side effects, psychotic symptoms in the 24 
previous episode, low pre-morbid functioning, the number of prior episodes, prior hospital 25 
admissions, and younger age of onset) [13,15,19-23], social characteristics (lack of social support 26 
and stigma) [24,25] and cognitive impairment [4,26,27]. The association of symptom severity, 27 
medication side effects, stigma, and cognitive impairment with functional impairment is consistent 28 
across studies [17].  29 
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There is generally a lack of evidence regarding factors that are associated with functional 1 
impairment among people with SMD in LMICs. This study aimed, therefore, to elucidate the 2 
association of demographic, economic, social and clinical factors with functional impairment of 3 
people with enduring SMD in a rural African setting in order to inform service planning and 4 
development. In view of findings of previous studies and our own qualitative explorations and 5 
observations, we hypothesized that diagnostic category, severity of symptoms, medication side 6 
effects and internalized stigma would be associated with functional impairment in people with 7 
SMD.  8 
Methods  9 
Study design  10 
The cross-sectional baseline data of the TaSCS (Task Sharing the Care of Severe Mental 11 
Disorders) trial [28] was used in this analysis. The aim of the TaSCS trial is to determine the 12 
effectiveness and cost-effectiveness of task-sharing mental health care for people with SMD in 13 
primary health care, compared to psychiatric nurse-led mental health care [29].  14 
Study setting and context  15 
The study was conducted in the town of Butajira and surrounding districts, located around 130km 16 
south of Addis Ababa, the capital city of Ethiopia. The study area is found in the Gurage and Silti 17 
Zones of the Southern Nations, Nationalities and People’s Region (SNNPR) of Ethiopia. Although 18 
there are both urban and rural dwellers, the area is predominantly rural. The area has diverse 19 
climatic and topographic features. Farming is the main means of livelihood in rural areas, whereas 20 
small scale trading is common in the towns. While maize is the main subsistence grain in the 21 
lowland areas, khat and chili pepper are the main cash crops. The highlanders mainly live on 22 
“kocho” (bread made from false banana trees). The area is also diverse in terms of ethnic identity 23 
with predominance of the Gurage and Silti ethnic groups. The majority of the population is either 24 
Muslim or Orthodox Christian by religion. Mental health research has been ongoing in the Butajira 25 
area for over 15 years. It is the site for a large, population-based cohort study looking at the course 26 
and outcome of schizophrenia, bipolar disorder and major depressive disorder [30], known as the 27 
Butajira SMD study. The TaSCS trial was nested within the Butajira SMD study after the study 28 
had been running for around 12 years. 29 
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People in the Butajira area use both traditional and biomedical treatment methods for their mental 1 
health problems. At the time of this study, biomedical mental health care was limited to the out-2 
patient psychiatric unit at Butajira General Hospital. This service was provided by two psychiatric 3 
nurses. 4 
Participants and recruitment  5 
The details of the characteristics of the sample and the recruitment procedure have been reported 6 
elsewhere [28]. Nevertheless, we briefly described the sample and the recruitment procedure as 7 
follows. Participants were recruited from the Butajira SMD cohort and from attendees at the 8 
Butajira General Hospital psychiatric out-patient clinic. Initially, our plan was to recruit the sample 9 
from the Butajira SMD cohort because it was community ascertained, but we did not have a big 10 
enough sample for the study. So, that is why we then decided to recruit also from the Butajira 11 
General Hospital psychiatric outpatient clinic. Inclusion criteria defined people with enduring 12 
SMD who had a need for ongoing care: those who were on psychotropic medication, currently 13 
symptomatic or had experienced relapse in the preceding two years. The sample size for the study 14 
was 324. A total of 218 participants were recruited from 507 people who were in the Butajira SMD 15 
cohort. Among those who were in the cohort, 40 refused, 32 were not contactable, 187 had no 16 
ongoing need for mental health care, 2 were restrained at home, 1 was mourning a loss, 4 had died, 17 
2 were profoundly deaf, 1 was imprisoned, 2 had just given birth, 10 were too unwell to be 18 
transported to screening site, 7 lacked capacity to consent and actively refused and 1 caregiver was 19 
not willing to bring the patient for screening. Only three potentially eligible participants refused to 20 
participate. The remaining participants  (n=106) were recruited from consecutive attendees at the 21 
psychiatric clinic at Butajira General Hospital who had been in contact with services for at least 22 
two years, were aged 25 to 65 years and who resided in the geographical catchment area of the 23 
Butajira SMD study. Twelve people who were screened and potentially eligible did not consent to 24 
participate. We considered the criteria about age and time since illness started to make the two 25 
sub-samples more similar. Also, most important is that both sub-samples were defined in relation 26 
to needing ongoing care. 27 
For participants recruited from the Butajira SMD study, historical diagnosis of SMD at the time 28 
of recruitment for the cohort was made using Schedules for Assessment in Neuropsychiatry 29 
(SCAN) [31]. For recruits from the Butajira General Hospital psychiatric out-patient clinic, new 30 
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SCAN diagnoses were made by psychiatrists who had been trained by a psychiatrist who had 1 
training at an accredited SCAN training centre.  2 
In addition to service users, we also included caregivers in our sample. Caregivers were defined 3 
as close family members (parents, sons/daughters, siblings or husband/wife) who were living with 4 
the person with SMD. After we finished recruiting the service users, we determined the caregiver 5 
of each service user using the above criteria.  6 
Assessment of functional impairment  7 
The 12 item version of the World Health Organization Disability Assessment Schedule 8 
(WHODAS-2.0) and the Butajira Functioning Scale (BFS) were used to assess functional 9 
impairment. The WHODAS is a generic, non-health condition specific, cross-cultural measure of 10 
activity limitations and social restrictions of a person in the past 30 days [32,33]. It is available in 11 
12 and 36 item versions, can be self-administered or interviewer administered and responses can 12 
be provided by the person with the health condition, a caregiver or a clinician [34,35]. The 13 
psychometric properties of the WHODAS have been established in a number of studies [36-39]. 14 
The WHODAS has also been adapted and validated in different languages and cultures [33,35,40], 15 
including in the rural Ethiopian setting [41]. The BFS is a local functioning scale developed for 16 
people with SMD in a rural African context and piloted in the district where the current study was 17 
conducted. The BFS was developed following standard procedures, including a qualitative study 18 
[42], review of previous scales, free listing and pile sorting exercise, expert consensus, cognitive 19 
interviewing and pilot testing. The BFS has 33 shared items for men and women and 8 women-20 
only items in three domains: self-care, work and social functioning [43]. The BFS is easy and fast 21 
to administer, with excellent internal consistency, construct and convergent validity and acceptable 22 
sensitivity to change over time. We used both the WHODAS and the BFS to assess functional 23 
impairment because we found in our previous validation studies [41,43] in that the two instruments 24 
complement with each other. Both the WHODAS and the BFS were administered to service users 25 
and caregivers.   26 
Clinician-administered measures 27 
The expanded version of the Brief Psychiatric Rating Scale (BPRS-E) was used to assess symptom 28 
severity. BPRS-E is a 24- item clinician administered symptom scale, which covers four domains 29 
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of symptoms of SMD (positive symptoms, negative symptoms, anxiety and depressive symptoms 1 
and manic excitement or disorganization) [44]. The BPRS-E has been used widely to detect clinical 2 
improvement in response to an intervention [45]. BPRS-E has been used previously in Ethiopia 3 
[43,46]. Psychiatric nurses who received training and ongoing supervision administered the BPRS-4 
E. They were found to have good inter-rater reliability.   5 
The Composite International Diagnostic Interview (CIDI) substance abuse module was used to 6 
assess khat use. The CIDI substance abuse module is a fully structured interview that ascertains 7 
the diagnosis of alcohol, tobacco and nine classes of psychoactive drugs. Excellent Kappa values 8 
for individual alcohol and drug symptoms have been reported for the CIDI substance abuse module 9 
[47]. Problematic khat use was operationalized in this study as endorsing any of the items of the 10 
CIDI relating to khat abuse or dependence. The Mini International Neuropsychiatric Interview 11 
(MINI) Suicidality Scale was used to assess self-harm and suicidal behaviors, including thought, 12 
intent and attempt. Each item is scored yes or no and weighted according to its estimated 13 
contribution to risk level. The MINI Suicidal Scale has been shown to be valid as a screen for the 14 
risk of suicidal behaviors [48]. Medication side effects were assessed using the Antipsychotic Side 15 
effects Checklist (ASC). The ASC was designed to assess a range of commonly encountered side-16 
effects of antipsychotic medications. Clinical characteristics, including the course of psychosis and 17 
number of psychotic episodes were determined using the Life Chart Schedule (LCS) [49]. 18 
Lay-interviewer administered measures 19 
Self-stigma was assessed using the Internalized Stigma of Mental Illness (ISMI) scale. The ISMI 20 
is a 29 item scale designed to measure the subjective experience of stigma, with five sub-scales 21 
(alienation, stereotype endorsement, perceived discrimination, social withdrawal, and stigma 22 
resistance) [50]. The ISMI has high internal consistency and test-retest reliability, and with good 23 
evidence  in its convergent and construct validity [51]. The ISMI scale has been used across a wide 24 
range of languages and cultures [50]. The ISMI was used in a previous facility-based study in 25 
Ethiopia and found to have good construct validity and internal consistency [52]. An eight item, 26 
structured self-reported medication adherence measure, the Morisky Medication Adherence Scale 27 
[53], was employed to assess the extent to which patients were adherent to their respective 28 
medication. A structured self-report demographic, social and economic characteristics 29 
questionnaire was used to collect data on sex, age, urban-rural residence, ethnic group, religion, 30 
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marital status, educational status, ownership of household assets, food security and self-sufficiency 1 
and relative wealth of the participants. Experienced diploma holder data collectors were trained 2 
for two days to administer the lay-interviewer administered measures. 3 
Data management and analysis  4 
Data were double entered into an electronic Case Report Form using OpenClinica [54]. Data 5 
analysis took place using Stata Version 13. Frequencies and percentages were used to summarize 6 
categorical, socio-demographic and clinical characteristics, whereas mean and standard deviation 7 
were used for summarizing the continuous variables. Negative binomial regression models, for 8 
service user reported and caregiver reported scores of the WHODAS and the BFS, were fitted 9 
separately in order to see consistency of findings. Multivariable negative binomial regression 10 
models were fitted to assess the association of demographic, social, economic and clinical factors 11 
with functional impairment in people with SMD. We used negative binomial regression because 12 
WHODAS and BFS scores were not normally distributed and only non-negative integer values are 13 
possible. Crude and adjusted relative risks (RR) were used to estimate the strength of association 14 
between the independent and dependent variables. All statistical tests were set at α = 0.05 for 15 
significance. 16 
Ethical considerations  17 
Ethical approval for the TaSCS trial was obtained from several international and local institutes: 18 
the Institutional Review Board of the College of Health Sciences, Addis Ababa University 19 
(Reference Number 030/12/Psy), the AHRI-ALERT Ethics Review Committee (Reference 20 
Number P037/13), the National Research Ethics Review Committee of Ethiopia (Reference 21 
Number 3.10/758/07), the Food, Medicine and Health Care Administration and Control Authority 22 
of Ethiopia (Reference Number 02/6/22/13), the University of Cape Town Human Research Ethics 23 
Committee (Reference Number 226/2011) and the United States of America’s National Institute 24 
of Mental Health Data Safety and Monitoring Board (DSMB). Written informed consent was 25 
obtained from most of the participants after the nature of the study and the information sought had 26 
been fully explained. The study included a few people (n= 10) with SMD who lacked capacity to 27 
consent to participate, were not actively refusing and had a guardian to give permission. During 28 
the study period, participants were provided with free treatment for both their mental and physical 29 
health problems.  30 
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Results  1 
Characteristics of the participants  2 
A total of 324 people with SMD participated in the study. Socio-demographic characteristics are 3 
presented in Table 1. Of the total sample, 47.1% (n=137) had schizophrenia, 35.5% (n= 116) had 4 
bipolar disorder and 21.9% (n=71) had major depressive disorder. Nearly half of the participants 5 
had either a continuous (27.5%) or episodic (20.1%) course for psychotic symptoms. Three 6 
quarters of participants receiving medication reported one or more medication side effects; 13.6% 7 
of the participants reported suicidal ideation in the past one month; and 6.8% reported problematic 8 
khat use. See Table 1. 9 
Factors associated with WHODAS-2.0 scores  10 
The mean score of the service user responses of the WHODAS was 22.3 (SD= 9.0) and of the 11 
caregiver responses was 24.7 (SD= 10.6) out of the maximum score of 60. Results from both the 12 
univariate and multivariable negative binomial regression models of the service user and caregiver 13 
reported WHODAS scores are presented in Table 2. In the multivariable model of service user 14 
reported WHODAS scores, increasing age, rural residence, being unmarried, lower perceived 15 
relative wealth, major depressive disorder, continuous course for psychosis, increasing scores of 16 
BPRS-E, increasing scores of internalized stigma and reporting two or more medication side 17 
effects were significantly associated with greater functional impairment.  18 
In the multivariable model of caregiver reported WHODAS scores, the same factors were found 19 
to be associated with functional impairment. However, major depressive disorder, continuous 20 
course for psychosis and lower perceived relative wealth were not significantly associated. 21 
Christian religion was significantly and negatively associated with functional impairment.  22 
Factors associated with BFS scores  23 
The mean score of the service user responses from the BFS was 65.7 (SD= 28.5) and of the 24 
caregiver responses 76.4 (SD= 33.8) out of the maximum score of 165. Results from the univariate 25 
and multivariable negative binomial regression models of service user and caregiver reported BFS 26 
scores are presented in Table 3. As with the WHODAS, we found increasing age, being unmarried, 27 
lower perceived relative wealth, continuous course of psychosis, increasing scores of BPRS-E, 28 
increasing scores of internalized stigma and two or more medication side effects to be associated 29 
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with greater functional impairment. However, while increasing scores of MINI Suicidal Scale 1 
scores were found to be associated with greater functional impairment in addition to the above 2 
factors, rural residence and major depressive disorder were not significantly associated.   3 
In the multivariable model of caregiver reported BFS scores, the same factors were significantly 4 
associated with functional impairment. Nevertheless, Christian religion was significantly 5 
associated with lower functional impairment and rural residence and problematic khat use were 6 
significantly associated with greater functional impairment. Continuous course of psychosis, 7 
increasing age and MINI Suicidal Scale scores were not associated with functional impairment.  8 
Discussion  9 
In this cross-sectional study of people with enduring SMD in a rural African setting, increasing 10 
age, being unmarried, rural residence, perceived lower relative wealth, continuous course of 11 
psychosis, higher symptom severity, internalized stigma and two or more medication side effects 12 
were consistently and significantly associated with functional impairment. Service user reported 13 
and caregiver reported scores on both the cross-cultural WHODAS and the contextually valid BFS 14 
measures gave similar patterns of associations. The study identified symptom severity, continuous 15 
course of psychosis, internalized stigma and medication side effects as important factors associated 16 
with functional impairment in people with severe and enduring SMD. The study confirmed that 17 
risk factors of functional impairment in people with SMD from high income country settings are 18 
also found to be important in LMIC settings.  19 
A negative association was found between the diagnostic category of bipolar disorder and 20 
caregiver reported WHODAS scores and between both bipolar disorder and major depressive 21 
disorder and service user reported BFS scores, when compared to schizophrenia. In the 22 
multivariable models, however, a significant association was found only between major depressive 23 
disorder and service user reported WHODAS scores. Our sample was selected on the basis of 24 
needing ongoing mental health care, which might explain the similarity in level of functional 25 
impairment across diagnostic groups. Nonetheless, our finding is in keeping with the evidence 26 
base [11-13,22], which indicates that the severity of symptoms, medication side effects, stigma 27 
and cognitive impairment are more important than diagnosis to predict functional impairment [17].  28 
12 
 
Among the socio-demographic factors considered in this study, increasing age and rural residence 1 
were positively associated with greater functional impairment, whereas being married was 2 
associated with lower levels of functional impairment. This is consistent with previous Ethiopian 3 
studies [8-10] and studies from elsewhere in the world [17]. Activity limitations and restrictions 4 
in participation are likely to increase with increasing age of living with severe mental illness due 5 
to deterioration of independent living skills, restricted social relationships, and comorbid medical 6 
and mental health conditions [55]. These may arise from the illness itself, medication side effects 7 
and stigma and discrimination. With regards to marital status, married people are likely to have 8 
the necessary social support to be more functional; and in addition to this there is also a likely 9 
social obligation to engage in several social activities compared to unmarried people. There is also 10 
a possibility that this association is due to reverse causality, in that better functioning people are 11 
more likely to get married and stay married. Our finding that people from rural areas are likely to 12 
have more functional impairment than urban residents is contrary to the widely held assumptions 13 
[56]. One possible explanation is that the kinds of activities rural residents are expected to perform, 14 
such as farming, are more difficult than activities of urban residents who are engaged in petty 15 
trade, office work or other small scale businesses. Therefore, rural residents are more likely to 16 
report difficulties of accomplishing those activities. An alternative explanation could be our use of 17 
culturally validated measures of functioning which are able to detect functional impairment in this 18 
rural setting. Residual confounding by socio-economic status might also contribute to the observed 19 
association. 20 
Contrary to our expectation, economic variables, including composite scores obtained from several 21 
asset indicators as well as indicators of food security and self-sufficiency were not found to be 22 
associated with functional impairment, both in the univariate and multivariable analyses. Previous 23 
cross-sectional studies found that lower socio-economic status was associated with greater 24 
functional impairment, particularly in the interpersonal domain [57] and higher socio-economic 25 
status was associated with functional recovery [58]. Low variability in the socioeconomic status 26 
in this rural low-income setting may have contributed.  Furthermore, we only used a one-item 27 
crude indicator of food insecurity; in a neighbouring district, using a validated scale to measure 28 
food insecurity, an association between disability and food insecurity was observed in people with 29 
SMD [59]. However, the consistent association between lower perceived relative wealth and 30 
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functional impairment is in keeping with our previous qualitative study [42] which suggested that  1 
the impact of SMD on functioning may be moderated by economic status.  2 
Of the clinical characteristics considered, symptom severity and medication side effects were 3 
positively associated with functional impairment consistently in all the models estimated. There is 4 
generally a lack of evidence on the impact of medication side effects on the day to day functioning 5 
of people with SMD. Only first-generation antipsychotic medications are available in the study 6 
site, with a reportedly high burden of sedative and movement-related side effects [60]. In our 7 
previous qualitative study [42], service user and caregiver participants emphasized medication side 8 
effects as important factors for the day-to-day functioning of people with SMD. Another 9 
qualitative study in the same setting [61] found that medication side effects might contribute to 10 
non-adherence due to a desire to preserve functioning over symptom control. However, medication 11 
adherence was not found to be associated with functional impairment in our study. This may be 12 
attributed to our sample; we included stabilized people with SMD who had been in mental health 13 
care for more than 15 years. The other reason may be because Butajira SMD study participants 14 
were followed-up by project outreach workers who provided support with medication adherence. 15 
Our reliance on a self-report measure of adherence may also have under-estimated non-adherence 16 
due to social desirability bias. Although this is not consistent across measures and respondents, 17 
problematic khat use was associated with greater functional impairment. More specifically, in the 18 
univariate models, problematic khat use was associated with increasing patient-reported and 19 
caregiver-reported WHODAS scores and increasing caregiver-reported BFS scores. In the 20 
multivariable models, problematic khat use was associated only with increasing caregiver-reported 21 
BFS scores. There is lack of evidence regarding the association between khat use and functional 22 
impairment in people with SMD. A previous qualitative study in the same setting as this study 23 
found that people with SMD use khat to try to improve functioning [62]. This may be a reflection 24 
of reverse causality or perhaps khat does not actually improve functioning. 25 
The association between clinical or illness related characteristics and functional impairment that 26 
we found in this study is consistent with the literature. A recent prospective cohort study among 27 
people with severe mental illnesses in China found a strong association between symptom severity 28 
and levels of functioning [23]. Bottlender and colleagues [13] concluded that the severity of illness 29 
symptoms and not the diagnosis of a mental disorder is the most significant factor in determining 30 
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the level of functional impairment. In a ten year prospective study [19], participants with more 1 
severe psychotic symptoms demonstrated significantly more impairment in occupational 2 
functioning, irrespective of diagnosis. Hence, our findings emphasize the importance of achieving 3 
symptom remission and dealing with medication side effects as crucial aspects of the recovery 4 
process.  5 
This study indicated that there is consistency between the responses obtained from the WHODAS 6 
and BFS measures in the kinds of factors that are found to be associated with functional 7 
impairment. Consistent association was found between symptom severity, internalized stigma, 8 
medication side effects and poverty with scores of functional impairment obtained from the 9 
WHODAS or the BFS. This is expected since our validation study of the BFS found that the two 10 
instruments have strong convergent validity [43]. Minor differences between the BFS and 11 
WHODAS relate to the association with diagnosis, MINI Suicidality scores and Khat use.  The 12 
MINI Suicidality score was associated with scores on the service user reported BFS scores. 13 
Problematic Khat use was associated with the caregiver reported BFS scores. These differences 14 
indicate that the BFS, as a contextual and disease specific measure, may be more sensitive than 15 
the WHODAS. 16 
In order to optimize the functioning of people with SMD who have ongoing need for mental health 17 
care, it may be useful to deal with the factors that are found to be consistently associated with 18 
functional impairment. For instance, community level rehabilitation services may help to improve 19 
family life and reduce stigma [63]. Mental health care services need to be expanded and give 20 
attention to controlling residual symptoms and medication side effects. Improved access to care 21 
(providing care closer to home) may affect the adequacy of symptom control [28]. There is a need 22 
for advocacy services by mental health researchers and professionals and civic organizations such 23 
as mental health service user organizations for more choice of medication and service expansion. 24 
Strengths and limitations 25 
Strengths of the study include use of standardized clinician evaluations for assessment of the key 26 
clinical variables, rigorous data management and use of a community-based population for our 27 
study. In addition, functional impairment was measured using two instruments: a standard, cross-28 
cultural and locally validated instrument and a locally developed scale which was found to be 29 
15 
 
contextually relevant. Responses for the outcome variable were also obtained from both service 1 
users and caregivers. Our use of two functional impairment measures and responses from service 2 
users and caregivers bring consistency to the study findings. Most of the previous studies assess 3 
functional impairment with only one instrument and obtain responses only from service users. 4 
Nevertheless, the following limitations need to be taken into account while interpreting the 5 
findings of this study. Our study is cross-sectional, and therefore the direction of association cannot 6 
be determined. We were not able to measure cognitive impairment, which is found to be 7 
consistently and strongly associated with functional impairment in several previous studies [27]. 8 
Other potential confounders, such as lifestyle factors, were not measured and adjusted in the 9 
regression models. The medication side effect scale has not been validated in the rural Ethiopian 10 
context. We used two types of sample in this study: the Butajira SMD cohort and attendees at the 11 
Butajira General Hospital psychiatric out-patient clinic. The first is a community sample while the 12 
latter is a clinical sample which may not represent the general population. Those who come to the 13 
clinic for seeking treatment may be different from those who did not and this may bring about 14 
selection bias.  15 
Conclusions  16 
In order to optimize functioning in people with chronic SMD in this setting, services need to target 17 
residual symptoms, poverty, medication side effects and internalized stigma. Testing the impact 18 
of adjunctive community-based interventions to promote inclusion and recovery will be useful. 19 
Advocacy for less sedating medication options is also warranted. Further research is required, in 20 
rural low income country settings, to elucidate the prospective association of socio-demographic, 21 
socio-economic and clinical characteristics with functional impairment in people with SMD.  22 
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Table 1: Socio-demographic and clinical characteristics of participants (n=324)  1 
aSD: Standard deviation  2 
Characteristics    N % 
Socio-demographic characteristics    
Sex Female  109  33.6 
 Male  215  66.4 
Age (years)    Mean 40.5  aSD 10.96 
Marital status  Single  86  26.5 
 Married  207  63.9 
 Divorced  19 5.9 
 Widowed  12  3.7 
Residence  Urban 45 13.9 
 Rural  279  86.1 
Unable to read and write  Yes  170  52.6 
Number of years of education completed    Mean 2.5  SD 3.5 
Ethnicity  Gurage  256 79.0 
 Silti  60  18.5 
 Other  8 2.5  
Religion  Muslim  247  76.2 
 Orthodox Christian  43  13.3 
 Protestant  
Catholic  
31  
3 
9.6 
0.9  
Occupation  Employed/self-employed  32 9.9 
 Farmer  170 52.5 
 Housewife  68 21.0 
 Student  3 0.9 
 Unemployed  51 15.7  
gRelative wealth  Less  165  51.0 
 Same or more  158 49.0 
Clinical characteristics    
Diagnosis  Schizophrenia  137  42.3 
 Bipolar disorder  116 35.8 
 Major depressive disorder 71 21.9 
Course type for psychosis  Episodic  65  20.1 
 Continuous  89  27.5 
 Neither episodic nor continuous  17  5.3 
 Never psychotic for six months  153  47.2 
Suicide attempts in the last one year Yes  5  1.5 
Suicidal ideation in the past one month        Yes  44  13.6 
Total bMINI Suicidal Scale score   Mean 1.1  SD 2.3 
cBPRS-E total score   Mean 29.6  SD 7.3  
Total ISMI scored  
eWHODAS total score (service user version)  
WHODAS total score (caregiver version)  
fBFS total score (service user version)  
BFS total score (caregiver version)  
 Mean 54.3 
Mean 22.3 
Mean 24.7  
Mean 65.7 
Mena 76.4  
SD 15.8  
SD 9.0 
SD 10.6 
SD 28.5 
SD 33.8 
Medication adherence   Mean 5.9 SD 1.4  
Restrained in the past one month Yes  5  1.5 
Problematic Khat use  Yes  22 6.8 
Medication side effect  None  82  25.5 
 One  16  5.0 
 Two or more  223 69.5 
23 
 
bMINI: Mini International Neuropsychiatric Interview 1 
cBPRS-E: expanded version of the Brief Psychiatric Rating Scale 2 
 dISMI: Internalized stigma of mental illness  3 
eWHODAS: World Health Organization Disability Assessment Schedule  4 
fBFS: Butajira Functioning Scale  5 
gRelative wealth refers to an individual’s perception about his/her wealth relative to other people in the 6 
neighborhood 7 
 8 
 9 
 10 
 11 
 12 
 13 
 14 
 15 
 16 
 17 
 18 
 19 
 20 
 21 
 22 
 23 
 24 
 25 
 26 
 27 
 28 
 29 
 30 
 31 
 32 
 33 
 34 
 35 
 36 
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Table 2: Univariate and multivariable association of demographic, economic, social and clinical factors 1 
with WHODAS-2.0 scores  2 
Variables     aCRR (95% CI)        bARR (95% CI)  
  Patient-reported  Caregiver- 
reported   
Patient-reported  Caregiver-
reported  
Sex Female  1.0 1.0  1.0 1.0  
 Male  1.02 [0.93, 1.12] 1.15 [1.04, 1.26]  0.92 [0.84, 1.01]  0.98 [0.88, 1.10]  
Age   1.00 (1.00, 1.01]  1.00 [0.997, 1.004] 1.01 [1.002, 1.01]  1.004 [1.00, 1.01]  
Marital status  Single  1.0 1.0 1.0  1.0  
 Married  0.96 [0.87, 1.06] 0.87 [0.78, 0.96]  0.85 [0.78, 0.92]  0.81 [0.73, 0.90]  
 Never married  1.14 [0.97, 1.33]  1.01 [0.85, 1.19] 0.92 [0.81, 1.05]  0.89 [0.75, 1.05]  
Number of years of 
education completed   
 0.98 [0.97, 0.997] 0.99 [0.97, 1.00] 0.999 [0.988, 1.01] 0.99 [0.98, 1.01] 
Religion Muslim  1.0  1.0  1.0  1.0  
 Christian  0.90 [0.81, 0.99]  0.82 [0.74, 0.92]  0.97 [0.89, 1.05]  0.89 [0.81, 0.98]  
Residence Urban  1.0  1.0  1.0  1.0  
 Rural  1.12 [0.99, 1.27] 1.18 [1.03, 1.35] 1.13 [1.02, 1.26]  1.19 [1.05, 1.34]  
Asset   0.98 [0.95, 1.006] 0.99 [0.95, 1.02] 0.999 [0.97, 1.03]  1.01 [0.98, 1.04]  
Food security/self-
sufficiency  
 0.94 [0.91, 0.97]  0.97 [0.93, 1.00] 1.01 [0.98, 1.04]  1.01 [0.97, 1.04]  
Relative wealth Less  1.0  1.0 1.0  1.0  
 Same or more  0.79 [0.72, 0.85]  0.91 [0.83, 0.99] 0.83 [0.77, 0.89]  0.92 [0.84, 1.01]  
Diagnosis Schizophrenia  1.0  1.0  1.0  1.0  
 Bipolar disorder  0.96 [0.87, 1.06]  0.84 [0.76, 0.94] 1.08 [0.999, 1.16]  0.99 [0.90, 1.08]  
 Major depressive 
disorder  
1.10 [0.98, 1.22]  0.91 [0.81, 1.03] 1.16 [1.06, 1.28]  1.05 [0.94, 1.18]  
Course type for psychosis Episodic 1.0  1.0  1.0  1.0  
 Continuous  1.30 [1.16, 1.46]  1.36 [1.20, 1.54]  1.15 [1.04, 1.28]  1.08 [0.95, 1.22]  
 Neither  1.16 [0.96, 1.40]  1.17 [0.95, 1.45]  1.09 [0.94, 1.27]  1.03 [0.85, 1.23]  
 Never psychotic  0.91 [0.82, 1.02]  0.94 [0.84, 1.06]  0.91 [0.84, 0.99]  0.94 [0.85, 1.04]  
BPRS-Ec   1.02 [1.01, 1.03] 1.02 [1.018, 1.03]  1.01 [1.001, 1.01]  1.02 [1.01, 1.02]  
Total MINI scored   1.03 [1.01, 1.05] 1.01 [0.99, 1.03]  1.01 [0.99, 1.03]  0.997 [0.98, 1.02]  
Total ISMI scoree  1.01 [1.01, 1.02] 1.01 [1.007, 1.013] 1.01 [1.007, 1.01]  1.01 [1.004, 1.01]  
Problematic khat use No  1.0  1.0  1.0  1.0  
 Yes  1.25 [1.06, 1.48] 1.41 [1.18, 1.69] 1.08 [0.94, 1.23]  1.14 [0.97, 1.34]  
Medication side effect None  1.0  1.0  1.0  1.0  
 One  1.15 [0.94, 1.42] 1.15 [0.88, 1.38]  0.99 [0.84, 1.15]  0.95 [0.78, 1.15]  
 Two or more  1.19 [1.08, 1.31]  1.23 [1.11, 1.37]  1.17 [1.07, 1.27]  1.17 [1.06, 1.30]  
Medication adherence   1.00 [0.97, 1.03] 1.00 [0.97, 1.03]  0.99 [0.98, 1.02] 1.01 [0.98, 1.04]  
    Nf= 312 
Pseudo R²= 0.07 
Nf= 312 
Pseudo R²= 0.10  
aCRR: Crude Relative Risk 3 
bARR: Adjusted Relative Risk 4 
cBPRS-E: expanded version of the Brief Psychiatric Rating Scale 5 
dMINI: Mini International Neuropsychiatric Interview 6 
eISMI: Internalized stigma of mental illness 7 
fN: Number of observations  8 
 9 
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Table 3: Univariate and multivariable association of demographic, economic, social and clinical factors 1 
with BFS scores  2 
Variables                     aCRR (95% CI)       bARR (95% CI)  
  Patient-reported  Caregiver- reported   Patient-reported  Caregiver-
reported  
Sex  Female  1.0 1.0  1.0  1.0  
 Male  1.05 [0.95, 1.1.5]  1.16 [1.04, 1.28]  0.93 [0.84, 1.03] 0.96 [0.85, 1.07]  
Age   1.00 [0.99, 1.004]  0.999 [0.99, 1.00]  1.004 [1.00, 1.01] 1.003 [0.99, 1.01]  
Marital status  Single  1.0  1.0  1.0  1.0  
 Married  0.77 [0.69, 0.85]  0.76 [0.68, 0.85]  0.69 [0.63, 0.77]  0.72 [0.65, 0.80]  
 Never married  0.98 [0.83, 1.15]  0.93 [0.78, 1.11]  0.83 [0.71, 0.97]  0.83 [0.70, 0.99]  
Number of years of 
education completed   
 0.99 [0.98, 1.004] 0.99 [0.98, 1.01] 1.00 [0.99, 1.01]  0.99 [0.98, 1.01]  
Religion  Muslim  1.0  1.0  1.0  1.0  
 Christian  0.91 [0.82, 1.01]  0.84 [0.75, 0.94] 0.93 [0.84, 1.01]  0.89 [0.80, 0.98] 
Residence  Urban  1.0  1.0  1.0  1.0  
 Rural  1.07 [0.93, 1.22]  1.12 [0.97, 1.29]  1.11 [0.99, 1.25]  1.14 [1.005, 1.30]  
Asset  0.98 [0.95, 1.02]  1.003 [0.97, 1.04]  1.01 [0.98, 1.04] 1.03 [0.996, 1.06]  
Food security/self-
sufficiency  
 0.96 [0.93, 0.999]  0.99 [0.95, 1.03]  1.01 [0.98, 1.04] 1.01 [0.97, 1.05] 
Relative wealth  Less 1.0  1.0  1.0  1.0  
 Same or more  0.85 [0.78, 0.93]  0.94 [0.85, 1.03]  0.86 [0.79, 0.93]  0.89 [0.81, 0.97]  
Diagnosis  Schizophrenia  1.0  1.0  1.0  1.0  
 Bipolar disorder  0.86 [0.77, 0.95]  0.79 [0.71, 0.88]  1.03 [0.94, 1.12]  0.96 [0.87, 1.06]  
 Major depressive 
disorder  
0.97 [0.86, 1.09]  0.84 [0.74, 0.96]  1.08 [0.97, 1.21]  1.01 [0.90, 1.14]  
Course type for 
psychosis 
Episodic 1.0  1.0  1.0  1.0  
 Continuous  1.41 [1.25, 1.60]  1.46 [1.28, 1.66]  1.17 [1.04, 1.32]  1.12 [0.99, 1.28]  
 Neither  1.31 [1.07, 1.60]  1.26 [1.01, 1.57]  1.16 [0.97, 1.38]  1.05 [0.86, 1.27]  
 Never psychotic  0.99 [0.88, 1.11]  0.97 [0.86, 1.10]  0.99 [0.90, 1.10]  0.97 [0.88, 1.08]  
BPRS-Ec  1.02 [1.01, 1.03] 1.26 [1.02, 1.03] 1.01 [1.003, 1.02] 1.02 [1.01, 1.03]  
Total MINI scored  1.03 [1.01, 1.05] 1.00 [0.98, 1.02]  1.02 [1.00, 1.04]  0.99 [0.97, 1.01]  
Total ISMI scoree  1.01 [1.008, 1.014] 1.008 [1.005, 1.01]  1.01 [1.005, 1.01]  1.005 [1.00, 1.01]  
Problematic khat use  No  1.0  1.0  1.0  1.0  
 Yes  1.18 [0.99, 1.41] 1.48 [1.23, 1.80]  1.02 [0.87, 1.19]  1.24 [1.04, 1.47]  
      
Medication side effect  None  1.0  1.0  1.0  1.0  
 One  1.22 [0.98, 1.52]  1.24 [0.98, 1.56]  1.03 [0.86, 1.23]  1.05 [0.86, 1.27]  
 Two or more  1.22 [1.10, 1.35]  1.28 [1.15, 1.44]  1.16 [1.05, 1.28]  1.23 [1.10, 1.37]  
Medication adherence   0.997 [0.97, 1.03]  0.996 [0.96, 1.03]  1.005 [0.98, 1.03]  1.001 [0.98, 1.04]  
    Nf= 309 
Pseudo R²= 0.06 
Nf= 310 
Pseudo R²= 0.06 
aCRR: Crude Relative Risk 3 
bARR: Adjusted Relative Risk 4 
cBPRS-E: expanded version of the Brief Psychiatric Rating Scale 5 
dMINI: Mini International Neuropsychiatric Interview 6 
eISMI: Internalized stigma of mental illness 7 
fN: Number of observations  8 
